Transformative pain therapeutics
Changing the course of pain for patients who need it most
Who we are
Adynxx, located in San Francisco, is a clinical-stage biotechnology company developing a transformative technology platform addressing pain at its molecular roots. Adynxx’s unique approach is to transform pain management by approaching pain as a disease rather than a symptom.
Provide safe, non-opioid, long-term pain reduction with a single administration
Developing transformative, first-in-class therapies to address significant unmet medical needs
A proprietary platform of non-opioid, disease-modifying oligonucleotide therapeutics
Tackling high unmet need
Focusing on patients who have the greatest need for innovative pain treatments
News & Publications
Dec 13, 2018
SAN FRANCISCO, Calif., December 13, 2018 -- Adynxx, Inc., a clinical-stage biotechnology company focused on developing transformative therapies for pain and inflammatory diseases, today announced receipt of Notice of Award from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), for an award to support the clinical development of the company’s lead product candidate, brivoligide injection (brivoligide) for postoperative pain.
Meet our team
Experienced management team with a proven track record of success dedicated to improving the life of patients